{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29751792", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29751792, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study indicates that the genotype GG (wild-type) of POLR2A N764K is associated with a higher risk of grade 3 or 4 thrombocytopenia compared to the CT genotype, but it does not find significant correlations with overall survival (OS) for the other genotypes (GT + TT) in the context of gemcitabine treatment."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and gemcitabine in Disease:Non-Small Cell Lung Carcinoma (PMID 29751792), what p-value was reported for this association?", "answer": "= 0.080", "response": "The reported p-value for the association of rs2231142 (ABCG2 Q141K) with patient outcome in Non-Small Cell Lung Carcinoma treated with gemcitabine was p < 0.05."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "39811327", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 39811327, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study does not report any association between HLA-A *31:03* and a decreased likelihood of Stevens-Johnson Syndrome (SJS) when treated with carbamazepine, lamotrigine, or phenytoin."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:03 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMID 39811327), what confidence interval was reported?", "answer": "0.13\u20130.27", "response": "The study did not report a confidence interval for HLA-A*31:03 in relation to carbamazepine, lamotrigine, or phenytoin in the context of toxicity. In fact, HLA-A*31:03 was not mentioned in the results regarding associations with Stevens-Johnson Syndrome or other severe cutaneous adverse reactions."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "False. The confidence intervals for the odds ratios (ORs) reported in the study do not include the null value of 1.0 for the associations mentioned. However, since HLA-A*31:03 was not associated with any outcomes in the study, there is no specific OR or confidence interval for that allele."}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26555147", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26555147, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study indicates that the ABCB1 3435C>T SNP (genotype CC) does not show significant differences in carbamazepine metabolism compared to genotypes CT and TT."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2298771 and carbamazepine in Disease:Epilepsy (PMID 26555147), what p-value was reported for this association?", "answer": "> 0.05", "response": "The p-value reported for the association of rs2298771 (SCN1A c.3184A>G) with carbamazepine metabolism in epilepsy was not significant, as the study indicated no impact for this SNP. Therefore, no specific p-value is provided for this association in the results."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False. Since the study indicated no significant impact for the SNP rs2298771 (SCN1A c.3184A>G), it would not remain significant at an alpha level of 0.01."}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25278709", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25278709, is the following pharmacogenomic claim supported or contradicted: Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMID 25278709), what OR was reported?", "answer": "7.9", "response": "The odds ratio (OR) reported for the association of the rs8099917 G allele with null-response to treatment was 7.9 (95% CI: 1.99-31.18)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32695297", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32695297, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study indicates that the MTHFR rs1801133 TT genotype is associated with higher plasma methotrexate levels compared to the CC genotype, but does not provide evidence that allele G (associated with the CC genotype) is linked to methotrexate concentrations. Therefore, the statement that allele G is not associated with concentrations of methotrexate compared to allele T is supported by the findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801131 and methotrexate in Other:Acute lymphoblastic leukemia (PMID 32695297), what p-value was reported for this association?", "answer": "> 0.05", "response": "The p-value reported for the association between the MTHFR rs1801131 AC genotype and decreased hepatic toxicity was P<0.05."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24498053", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24498053, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs13242038 and heroin in Other (PMID 24498053)?", "answer": 619, "response": "There were 619 controls included in the study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28727815", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28727815, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **supported**. The study found that the *CYP3A4* rs35599367 variant (CYP3A4*22 allele) carriers had higher everolimus blood concentration compared to wild type patients (CC genotype), indicating that genotypes CT + TT are not associated with increased concentrations of everolimus compared to genotype CC."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "This annotation represents a **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and everolimus in Disease:Breast Neoplasms (PMID 28727815), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported no statistically significant association for *CYP3A5* rs776746 (genotype G>A) with everolimus concentrations, as it was mentioned that no significant differences were found for *CYP3A5*1 carriers. Therefore, a specific p-value for this association was not provided in the results."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "**False.** The finding for *CYP3A5* rs776746 was not statistically significant, as no significant differences were reported for *CYP3A5*1 carriers."}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28045923", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28045923, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **supported**. The study found that specific SNPs in the angiogenesis-related genes were associated with pathologic complete response (pCR) to bevacizumab, but it does not indicate that allele A is associated with a response compared to allele G. Therefore, the claim that allele A is not associated with response to bevacizumab is supported by the findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs17577 and bevacizumab in Disease:Breast Neoplasms (PMID 28045923)?", "answer": 33, "response": "The study did not specifically mention the inclusion of controls for rs17577 in relation to bevacizumab and breast neoplasms. It focused on the analysis of SNPs in patients receiving bevacizumab and chemotherapy, and while it referenced healthy subjects as controls in general, it did not provide a specific number for controls related to rs17577. Therefore, the exact number of controls for that specific SNP is not provided in the paper."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "**False.** The study does not provide a specific number of controls for rs17577, and it does not indicate that the dataset meets the minimum of N \u2265 30 for study controls."}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "990860", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 990860, is the following pharmacogenomic claim supported or contradicted: G6PD deficiency is not associated with Hemolysis when treated with trimethoprim. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The paper indicates that sulphamethoxazole (which is related to trimethoprim) only aggravated haemolysis in some individuals with G6PD deficiency, suggesting that trimethoprim does not have a consistent association with hemolysis in these patients."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of G6PD deficiency and trimethoprim in Toxicity (PMID 990860)?", "answer": 8, "response": "The study included a total of 12 cases of G6PD deficiency."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20362271", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20362271, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with increased risk of Crohn Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found that the SNP rs11805303, which includes allele G, did not show a statistically significant association with Crohn Disease (p = 0.4263, OR = 1.1253), indicating that allele G is not associated with increased risk of Crohn Disease."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2542151 (PMID 20362271), what OR was reported?", "answer": "1.0834", "response": "For the study of rs2542151, the reported odds ratio (OR) was 1.0834 for Crohn Disease."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False. The confidence interval for the OR of rs2542151 is (0.74\u20131.58), which includes the null value of 1.0."}]}
{"chain_id": "chain_000010", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28255319", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28255319, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study specifically discusses the effects of CYP2C19 and P2Y12 polymorphisms on platelet reactivity, but does not mention genotypes AG + GG in relation to increased platelet reactivity compared to genotype AA. Instead, it highlights that CYP2C19*2 and P2Y12 mutations are associated with high on-treatment platelet reactivity (HTPR), while CYP2C19*17 is associated with improved platelet reactivity."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2046934 and aspirin, clopidogrel in Efficacy (PMID 28255319), what confidence interval was reported?", "answer": "1.64\u20133.53", "response": "The study reported a confidence interval (CI) of 95% for the odds ratios (OR) associated with clinical endpoints related to the polymorphisms, specifically for CYP2C19*2 and P2Y12. For example, the odds ratio for CYP2C19*2 was 4.05 with a 95% CI of 1.28\u201312.77."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval for the odds ratio (OR) for CYP2C19*2 (1.28\u201312.77) excludes the null value of 1.0."}]}
{"chain_id": "chain_000011", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29318894", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29318894, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10264272 and tacrolimus in Disease:Kidney Transplantation, Disease:Transplantation (PMID 29318894), what p-value was reported for this association?", "answer": "= 0.269", "response": "The p-value reported for the association of rs10264272 with tacrolimus in the study was 0.269."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000012", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24141364", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24141364, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased minimal residual disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The paper discusses the association of GATA3 variants with Ph-like childhood acute lymphoblastic leukemia (ALL) and mentions the influence of GATA3 SNP genotype on early treatment response and risk of relapse, but it does not specifically address the association of allele A with increased minimal residual disease in the context of the mentioned treatments."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3824662 and asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine in Disease:Acute lymphoblastic leukemia (PMID 24141364), what p-value was reported for this association?", "answer": "= 0.039", "response": "The study does not report a specific p-value for the association of rs3824662 with the mentioned treatments (asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine) in the context of acute lymphoblastic leukemia. The reported p-values in the abstract pertain to the association of rs3824662 with Ph-like ALL and non-ALL controls, not specifically with treatment outcomes."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "**True.** The reported p-values for the association of rs3824662 with Ph-like ALL (P=2.17\u00d710\u221214 and P=1.05\u00d710\u22128) are both significantly less than the alpha level of 0.05, indicating statistical significance."}]}
{"chain_id": "chain_000013", "chain_family": "B_claim\u2192presence_absence", "pmid": "34158603", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34158603, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 34158603, rs74569896 is associated with Efficacy, Toxicity, Metabolism/PK outcomes for aspirin, clopidogrel. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 34158603 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 34158603 reports quantitative statistics for rs74569896, including a hazard ratio (HR) of 1.90 and a p-value of 1.31 \u00d7 10^\u22126 for its association with major adverse cardiovascular events (MACE)."}]}
{"chain_id": "chain_000014", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28696411", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28696411, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study found that allele A of rs6706232 in the UGT1A3 gene is associated with a better response to risperidone compared to allele G, with statistical significance (P=0.024)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs6313 and risperidone in Other:Schizophrenia (PMID 28696411), what p-value was reported for this association?", "answer": "= 1", "response": "The study reported a p-value of 0.447 for the association of rs6313 with risperidone response in schizophrenia."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False. The reported p-value of 0.447 is not significant at an alpha level of 0.01."}]}
{"chain_id": "chain_000015", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23809542", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23809542, is the following pharmacogenomic claim supported or contradicted: CYP2C19 *17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2C19*17 and clopidogrel in Efficacy (PMID 23809542), what p-value was reported for this association?", "answer": "= 0.01", "response": "The p-value reported for the association of CYP2C19*17 with clopidogrel active metabolite levels before adjustment for CYP2C19*2 was 0.04. After adjustment, the p-value was 0.59, indicating no significant association."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000016", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "27247849", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27247849, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of cognitive dysfunction due to opioids in people with Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found no significant associations between the analyzed SNPs, including those with allele T, and cognitive dysfunction in opioid-treated patients with cancer."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2160652 and opioids in Disease:Neoplasms (PMID 27247849)?", "answer": 98, "response": "A total of 202 cases were included in the study of rs2160652 and opioids in Disease: Neoplasms (PMID 27247849)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000017", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3778151 and heroin in Toxicity (PMID 25744370), what p-value was reported for this association?", "answer": "= 3E-3", "response": "The p-value reported for the association of rs3778150 with heroin addiction was P=6.3\u00d710^\u22125."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000018", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29706892", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29706892, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with severity of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found that the associations between genetic markers and the risk of severe neutropenia were not significant in the replication cohort, indicating that allele C is not associated with the severity of neutropenia compared to allele T."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2972164 and fluorouracil, irinotecan, leucovorin in Disease:Colorectal Neoplasms (PMID 29706892), what OR was reported?", "answer": "1.34", "response": "For the study of rs2972164 and fluorouracil, irinotecan, leucovorin in Disease: Colorectal Neoplasms, the reported odds ratio (OR) was 0.36 (95% CI: 0.16\u20130.82) in the discovery cohort."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence interval (0.16\u20130.82) for the OR does not include the null value of 1.0."}]}
{"chain_id": "chain_000019", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20031608", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20031608, is the following pharmacogenomic claim supported or contradicted: Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1051375 and verapamil in Disease:Coronary Artery Disease (PMID 20031608), what confidence interval was reported?", "answer": "1.67\u201312.67", "response": "The confidence interval reported for the rs1051375 A/A genotype associated with a reduction in the primary outcome among those randomized to verapamil SR treatment compared to atenolol treatment was 95% CI 0.32-0.92."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000020", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20665488", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20665488, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found that the genotype CC of the *CDA* A-76C variant was associated with a poorer response to gemcitabine-based therapy compared to the AC/CC genotypes, indicating that CC is not associated with an increased response."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs9394992 and gemcitabine in Disease:Pancreatic Neoplasms (PMID 20665488), what HR was reported?", "answer": "1.08", "response": "For the study of rs9394992 (hENT1 C913T) and gemcitabine in pancreatic neoplasms, the reported hazard ratio (HR) for progression-free survival (PFS) was 3.25 (95% CI: 1.79\u20135.90) for patients carrying 3\u20134 at-risk genotypes."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence interval (95% CI: 1.79\u20135.90) for the HR does not include the null value of 1.0."}]}
{"chain_id": "chain_000021", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "22850190", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22850190, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs77005399 and sulfamethoxazole / trimethoprim in Disease:Infectious disease (PMID 22850190)?", "answer": 99, "response": "The study included 99 cases of patients with sulfonamide hypersensitivity."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000022", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23963862", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23963862, is the following pharmacogenomic claim supported or contradicted: Genotype CG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study identifies the genotype CG of the SNP rs139887 in the SOX10 gene as being associated with an increased risk of neurotoxicity in patients treated with platinum/taxane chemotherapy, including carboplatin and paclitaxel, compared to the CC and GG genotypes."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs139887 and carboplatin, docetaxel, paclitaxel in Disease:Ovarian Neoplasms (PMID 23963862), what OR was reported?", "answer": "1.77", "response": "The odds ratio (OR) reported for the genotype CG of rs139887 in the SOX10 gene was 1.77, with a 95% confidence interval of (1.21, 2.59)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (1.21, 2.59) does not include the null value of 1.0."}]}
{"chain_id": "chain_000023", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "35457347", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 35457347, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity and Fetal Alcohol Syndrome as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1800497 and methylphenidate in Other:Attention Deficit Disorder with Hyperactivity, Other:Fetal Alcohol Syndrome (PMID 35457347)?", "answer": 114, "response": "The study included 114 cases diagnosed with Attention Deficit Disorder with Hyperactivity (ADHD) and high prenatal alcohol exposure (hPAE), which encompasses those with and without morphological features of Fetal Alcohol Syndrome (FAS)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000024", "chain_family": "B_claim\u2192presence_absence", "pmid": "36833383", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 36833383, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 36833383, rs4149056 is associated with PD, Metabolism/PK outcomes for atorvastatin, simvastatin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 36833383 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 36833383 reports quantitative statistics, including odds ratios (OR) and confidence intervals (CI) for the association between the SLCO1B1 c.521T>C genotype and various outcomes related to statin therapy, such as dose change and treatment discontinuation. However, it does not find a statistically significant association, as indicated by the reported ORs and their confidence intervals."}]}
{"chain_id": "chain_000025", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study focuses on the association of the rs1799971 allele A with heroin addiction, but it finds that allele C of the rs3778150 SNP is associated with increased risk of heroin addiction, not allele A."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3823010 and heroin in Toxicity (PMID 25744370), what confidence interval was reported?", "answer": "1.1\u20131.37", "response": "The confidence interval reported for rs3823010 in association with heroin addiction was 1.10-1.37."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval for the odds ratio (OR) of rs3823010 (1.10-1.37) does not include the null value of 1.0."}]}
{"chain_id": "chain_000026", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26729753", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26729753, is the following pharmacogenomic claim supported or contradicted: Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that African American participants with the heterozygous genotype (TTA/del) for the SLC25A31 rs201279313 deletion had a better diastolic blood pressure response to atenolol monotherapy, metoprolol monotherapy, and atenolol add-on therapy compared to those with the wild-type genotype (TTA/TTA)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs201279313 and atenolol, hydrochlorothiazide, metoprolol in Disease:Hypertension (PMID 26729753), what p-value was reported for this association?", "answer": "= 1.10E-07", "response": "The p-value reported for the association of rs201279313 with diastolic blood pressure response to atenolol, metoprolol, and atenolol add-on therapy was 2.5*10^\u22128 in the 3-group meta-analysis."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000027", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "40281622", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40281622, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT is associated with increased likelihood of statin-related myopathy when treated with atorvastatin in people with Cardiovascular Disease, Diabetes Mellitus, Acute coronary syndrome or Dyslipidaemia as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study indicates that atorvastatin users with the SLCO1B1 rs4149056 variant (specifically the CC and CT genotypes) exhibited a twofold increased risk of statin-associated muscle symptoms (SAMS) compared to those with the TT genotype, particularly among females and Arabs."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4149056 and atorvastatin in Other:Cardiovascular Disease, Other:Diabetes Mellitus, Other:Acute coronary syndrome, Other:Dyslipidaemia (PMID 40281622), what OR was reported?", "answer": "2.202", "response": "The odds ratio (OR) reported for the study of rs4149056 and atorvastatin in the context of statin-associated muscle symptoms (SAMS) was 2.202 (95% CI: 1.287 to 3.811) for carriers of the C allele compared to non-carriers."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI: 1.287 to 3.811) does not include the null value of 1.0."}]}
{"chain_id": "chain_000028", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "38673067", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 38673067, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found that the wildtype ABCC2 -24C>T C allele is associated with a higher risk of developing acute graft rejection and/or acute tubular necrosis compared to the variant allele T carriers (adjusted Odd Ratios [aOR]: 27.675, p = 0.038)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs717620 and mycophenolic acid, tacrolimus in Other:Kidney Transplantation (PMID 38673067), what p-value was reported for this association?", "answer": "= 0.038", "response": "The p-value reported for the association of the wildtype ABCC2 -24C>T C allele with the risk of developing acute graft rejection and/or acute tubular necrosis was 0.038."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True. The finding is statistically significant at alpha = 0.05, as the p-value of 0.038 is less than 0.05."}]}
{"chain_id": "chain_000029", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "34910759", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34910759, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found no significant association between allele G of the OPRM1 SNPs and the dose of methadone, indicating that allele G is not associated with methadone dose compared to allele A."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs10485058 and methadone in Other:Opioid-Related Disorders (PMID 34910759)?", "answer": 1165, "response": "The study included 1,129 cases for the analysis of rs10485058 and methadone in the context of opioid-related disorders."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True. The dataset meets the minimum of N \u2265 30 for study cases, as it included 1,129 cases."}]}
{"chain_id": "chain_000030", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "33285053", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 33285053, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with decreased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that carriers with the G allele of rs2790 had a lower risk of developing grade 2\u20133 hand-foot syndrome (HFS) (OR, 0.58; 95% CI, 0.39 to 0.87; p=8.80\u00d710^\u22123)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3786362 and capecitabine in Other:Colorectal Neoplasms (PMID 33285053), what OR was reported?", "answer": "0.38", "response": "The odds ratio (OR) reported for rs3786362 in association with capecitabine-induced hand-foot syndrome (HFS) was 0.38 (95% CI, 0.21 to 0.70; p=1.89\u00d710^\u22123)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI, 0.21 to 0.70) does not include the null value of 1.0."}]}
{"chain_id": "chain_000031", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29097388", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29097388, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted. The study identifies allele T (specifically the major allele of SNP rs261316 in the gene ALDH1A2) as being associated with an increased odds of having uncontrolled blood pressure on combination therapy, not allele C."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs35123024 and atenolol, hydrochlorothiazide in Disease:Hypertension (PMID 29097388), what OR was reported?", "answer": "3.71", "response": "The odds ratio (OR) reported for rs35123024 in relation to uncontrolled blood pressure on combination therapy with atenolol and hydrochlorothiazide was 3.71 (95% CI: 2.13\u20136.45, P=3.46E\u201006)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI: 2.13\u20136.45) does not include the null value of 1.0."}]}
{"chain_id": "chain_000032", "chain_family": "B_claim\u2192presence_absence", "pmid": "27977335", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27977335, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 27977335, rs3766246 is associated with Toxicity outcomes for morphine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 27977335 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 27977335 does not report any quantitative statistic (p-value, odds ratio, or confidence interval) for the claim regarding rs3766246 being associated with toxicity outcomes for morphine."}]}
{"chain_id": "chain_000033", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "37198710", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 37198710, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The study indicates that the T allele (associated with the G2677T polymorphism) is linked to an increased risk of acute rejection, while the G allele is not associated with this risk."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1045642 and tacrolimus in Other:Kidney Transplantation (PMID 37198710), what p-value was reported for this association?", "answer": "= 0.01", "response": "The study did not report a p-value for rs1045642 specifically, as it focused on the C3435T and G2677T polymorphisms of the MDR1 gene. Therefore, there is no p-value available for rs1045642 in the context of this study."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "**True.** The reported p-values for the associations with the C3435T and G2677T polymorphisms were below 0.01, indicating that the associations would remain significant at an alpha level of 0.01."}]}
{"chain_id": "chain_000034", "chain_family": "B_claim\u2192presence_absence", "pmid": "16476706", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 16476706, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 16476706, rs671531 is associated with Toxicity outcomes for heroin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 16476706 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 16476706 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding rs671531 and its association with toxicity outcomes for heroin, as this SNP is not mentioned in the context of such an association in the paper."}]}
{"chain_id": "chain_000035", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23860526", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23860526, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with response to cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CG + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The study found that the \u2212634CC genotype is significantly associated with a shorter progression-free survival (PFS) in patients treated with metronomic cyclophosphamide, indicating that this genotype is related to treatment response."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2010963 and cyclophosphamide in Disease:Prostatic Neoplasms (PMID 23860526), what p-value was reported for this association?", "answer": "= 0.0485", "response": "The reported p-value for the association of the rs2010963 (\u2212634C/G) genotype with response to cyclophosphamide in prostate cancer was **0.0485**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True. The p-value of 0.0485 is less than the alpha level of 0.05, indicating statistical significance."}]}
{"chain_id": "chain_000036", "chain_family": "B_claim\u2192presence_absence", "pmid": "26607661", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26607661, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 26607661, SLCO1B1*1, SLCO1B1*15 is associated with Toxicity outcomes for enalapril. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 26607661 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 26607661 reports quantitative statistics for the claim, including odds ratios (OR) and confidence intervals (CI) for the association between SLCO1B1 variants and enalapril-induced cough. For example, the study found that the SLCO1B1 521C allele conferred a 2-fold relative risk of enalapril-induced cough (OR = 2.02, 95% CI = 1.34\u20133.04, P = 6.2 \u00d7 10\u22124). Additionally, haplotype analysis indicated a 6.94-fold increased risk (OR = 6.94, 95% CI = 1.30\u201337.07, P = 0.020) for SLCO1B1*15/*15 carriers."}]}
{"chain_id": "chain_000037", "chain_family": "B_claim\u2192presence_absence", "pmid": "34512362", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34512362, is the following pharmacogenomic claim supported, contradicted, or not reported: Genotypes CT + TT is associated with decreased concentrations of atorvastatin in men as compared to genotype CC. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 34512362 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 34512362 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) related to the claim about atorvastatin concentrations and genotypes CT + TT compared to CC. The study focuses on the pharmacokinetics of teneligliptin and its association with FMO3 and CYP3A4 polymorphisms, not atorvastatin."}]}
{"chain_id": "chain_000038", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28790841", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28790841, is the following pharmacogenomic claim supported or contradicted: UGT1A1 *6 + *28 is not associated with increased likelihood of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms or Lung Neoplasms as compared to UGT1A1 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of UGT1A1*1, UGT1A1*6, UGT1A1*28 and irinotecan in Other:Colorectal Neoplasms, Other:Lung Neoplasms (PMID 28790841), what p-value was reported for this association?", "answer": "= 0.7", "response": "The reported p-value for the association between UGT1A1*6/*28 and severe neutropenia or delayed diarrhea in lung cancer patients was not significant (P>0.05). For colorectal cancer patients, the p-value for severe delayed diarrhea associated with UGT1A1*6 was 0.042, and when considering both UGT1A1*6 and UGT1A1*28 together, it was 0.028. However, the specific p-value for neutropenia in colorectal neoplasms was not provided in the results."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000039", "chain_family": "B_claim\u2192presence_absence", "pmid": "22162992", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22162992, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 22162992, rs1045642 is associated with Toxicity, Metabolism/PK outcomes for olanzapine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 22162992 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 22162992 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs1045642 and its association with toxicity or metabolism/PK outcomes for olanzapine, as this specific claim is not addressed in the paper."}]}
{"chain_id": "chain_000040", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "18007983", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 18007983, is the following pharmacogenomic claim supported or contradicted: HLA-B *44:02 + *44:03 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Contradicted. The study found that HLA-B*44 alleles were present in 6.2% of TCE-induced hypersensitivity dermatitis patients but were absent in TCE-tolerant workers, indicating a weak association rather than a strong one."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of HLA-B*44:02, HLA-B*44:03 and trichloroethylene in Toxicity (PMID 18007983)?", "answer": 113, "response": "The study included 113 cases with TCE-induced hypersensitivity dermatitis. Among these, HLA-B*44 alleles were present in 6.2% (7 out of 113) of the patients."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000041", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "31066027", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 31066027, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:01 is associated with increased risk of drug-induced liver injury when treated with carbamazepine. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:01 and carbamazepine in Toxicity (PMID 31066027), what confidence interval was reported?", "answer": "2.47\u201323.67", "response": "The confidence interval reported for HLA-A*31:01 in relation to carbamazepine-induced toxicity was 95% CI 4.10\u201315.80."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000042", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "40405401", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40405401, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT is associated with decreased likelihood of Progression-free survival and overall survival when treated with doxorubicin in people with Hepatocellular Carcinoma as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that the presence of the heterozygous genotype (TC) at the CBR1 rs3787728 locus was associated with reduced overall survival (OS) and progression-free survival (PFS) compared to the homozygous CC genotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3787728 and doxorubicin in Other:Hepatocellular Carcinoma (PMID 40405401), what p-value was reported for this association?", "answer": "= 0.045", "response": "The reported p-value for the association between rs3787728 and doxorubicin outcomes in hepatocellular carcinoma was 0.04 for overall survival (OS) and 0.023 for progression-free survival (PFS)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000043", "chain_family": "B_claim\u2192presence_absence", "pmid": "38707740", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 38707740, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 38707740, UGT1A1*1, UGT1A1*6, UGT1A1*28 is associated with Dosage, Efficacy outcomes for fluorouracil, irinotecan, leucovorin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 38707740 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 38707740 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) specifically for the claim regarding UGT1A1*1, UGT1A1*6, and UGT1A1*28 being associated with dosage or efficacy outcomes for fluorouracil, irinotecan, and leucovorin. The study primarily focuses on the association of UGT1A1 polymorphisms with adverse events, specifically leukopenia and neutropenia, rather than efficacy outcomes."}]}
{"chain_id": "chain_000044", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "40741000", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40741000, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The paper identifies specific genetic variants associated with anthracycline-induced cardiotoxicity, but does not support the assertion that allele A is associated with increased likelihood of cardiotoxicity compared to allele C for daunorubicin or doxorubicin in children with neoplasms."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs17583889 and daunorubicin, doxorubicin in Other:Neoplasms (PMID 40741000), what OR was reported?", "answer": "1.84", "response": "For the study of rs17583889 and daunorubicin, doxorubicin in Other: Neoplasms, the reported odds ratio (OR) was **1.84**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**True.** The confidence interval for the OR (1.84; CI range 1.34\u20132.52) does not include the null value of 1.0."}]}
{"chain_id": "chain_000045", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study found that the rs3778150-C allele is associated with increased risk of heroin addiction, while the association of the T allele was not significant."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs511435 and heroin in Toxicity (PMID 25744370), what OR was reported?", "answer": "1.2", "response": "The odds ratio (OR) reported for rs511435 in relation to heroin addiction was 1.20 (95% CI: 0.93-1.59)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False. The confidence interval for the OR (0.93-1.59) includes the null value of 1.0."}]}
{"chain_id": "chain_000046", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "31090079", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 31090079, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study found that allele C (specifically rs1042714 C-allele carriers) is associated with a better heart rate-lowering response to both atenolol and metoprolol compared to allele G carriers."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1801253 and atenolol, metoprolol in Other:Tachycardia (PMID 31090079)?", "answer": 459, "response": "The study did not report any cases for rs1801253 in the context of atenolol or metoprolol treatment in individuals with Tachycardia. The results for rs1801253 were not significant in the analyzed cohorts, and specific case numbers for this SNP in the context of Tachycardia were not provided."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "False. The study did not include any cases for rs1801253 in the context of atenolol or metoprolol treatment in individuals with Tachycardia, which does not meet the minimum of N \u2265 30."}]}
{"chain_id": "chain_000047", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "8971426", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 8971426, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*17. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6*1, CYP2D6*2, CYP2D6*17 and debrisoquine in Metabolism/PK (PMID 8971426), what p-value was reported for this association?", "answer": "< 0.001", "response": "The abstract does not provide a specific p-value for the association between CYP2D6*17 and debrisoquine metabolism. Therefore, the p-value is not reported in the provided information."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "False."}]}
{"chain_id": "chain_000048", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "27566582", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27566582, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study indicates that the presence of the variant allele C of *ABCB1* rs9282564 is associated with higher AUC_0-48_ values and higher peak MTX concentrations compared to the homozygous TT genotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs9282564 and methotrexate in Metabolism/PK (PMID 27566582)?", "answer": 59, "response": "The study included 59 cases."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000049", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "39974498", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 39974498, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted. The study indicates that the SCN1A rs121917953 T/A (D188V) polymorphism, specifically the AT genotype, is associated with a higher risk of drug resistance compared to the TT wild-type, suggesting that allele A is indeed associated with increased resistance to antiepileptics."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs121918623 and antiepileptics in Other:Epilepsy (PMID 39974498), what p-value was reported for this association?", "answer": "= 1", "response": "For the association of rs121918623 C/T (T875M) polymorphism with antiepileptic drug resistance, no significant difference in genotype distribution was observed, and the reported p-value was 1.00."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
